Rheumatic Heart Disease
Conditions
Brief summary
VKA in RHD patients with MHV: our current status
Detailed description
Vitamin K Antagonist in Rheumatic heart disease patients with mechanical heart valves: Our Current Status
Interventions
None listed
Sponsors
Ahmed Hassan Rostom Ibrahim
Study design
Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Confirmed presence of a mechanical heart valve. * Aged ≥18 years
Exclusion criteria
* Pregnancy. * Active bleeding disorders. * Severe liver/kidney disease (if affecting anticoagulation).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 2. Correlation Between TTR and Patient-Specific Factors | Baseline | Assesses the relationship between INR control and factors such as age, comorbidities, adherence, vitamin K intake, and medication use based on data collected at the single study visit. |
| Time in therapeutic range (TTR) for warfarin. | Baseline | TTR status will be calculated using the most recent INR value and patient records to determine whether INR is within the target therapeutic range (2.0-3.5) at the time of data collection. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 1. Number of Participants With Reported Bleeding Events (Major or Minor) | Baseline | Presence or absence of self-reported or documented major/minor bleeding events prior to or at the time of data collection. |
| Number of Participants With Thromboembolic Events | Baseline | History of stroke, valve thrombosis, or systemic embolism collected from medical records or patient report during the study visit. |
| Rate of Patient Adherence to Warfarin Therapy | Baseline | Adherence assessed via patient self-report and/or pill count at the single study visit. |
Contacts
Primary ContactAhmed Hassan Rostom, Master
Outcome results
None listed